Advertisement

Topics

Lexicon Pharma opts to co─promote sotagliflozin with Sanofi in type 1 diabetes in US

06:48 EDT 2 Aug 2017 | PharmaBiz

Lexicon Pharmaceuticals announced that it has exercised its option under its collaboration and license agreement with Sanofi to co─promote sotagliflozin, an investigational oral dual inhibitor of sodium─glucose cotransporters 1 and 2

Original Article: Lexicon Pharma opts to co─promote sotagliflozin with Sanofi in type 1 diabetes in US

NEXT ARTICLE

More From BioPortfolio on "Lexicon Pharma opts to co─promote sotagliflozin with Sanofi in type 1 diabetes in US"

Quick Search
Advertisement
 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...